JP6608698B2 - Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト - Google Patents

Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト Download PDF

Info

Publication number
JP6608698B2
JP6608698B2 JP2015514525A JP2015514525A JP6608698B2 JP 6608698 B2 JP6608698 B2 JP 6608698B2 JP 2015514525 A JP2015514525 A JP 2015514525A JP 2015514525 A JP2015514525 A JP 2015514525A JP 6608698 B2 JP6608698 B2 JP 6608698B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
sequence
polypeptide
single variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015514525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015525211A (ja
JP2015525211A5 (enExample
Inventor
オウス・ダンカー，ヴェルベック
ノルテ，フリードリッヒ
ストルトラー，カトリーン
レーレマンス，トーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitatsklinikum Hamburg Eppendorf
Original Assignee
Universitatsklinikum Hamburg Eppendorf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitatsklinikum Hamburg Eppendorf filed Critical Universitatsklinikum Hamburg Eppendorf
Publication of JP2015525211A publication Critical patent/JP2015525211A/ja
Publication of JP2015525211A5 publication Critical patent/JP2015525211A5/ja
Application granted granted Critical
Publication of JP6608698B2 publication Critical patent/JP6608698B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015514525A 2012-06-01 2013-05-31 Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト Active JP6608698B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654417P 2012-06-01 2012-06-01
US61/654,417 2012-06-01
PCT/EP2013/061257 WO2013178783A1 (en) 2012-06-01 2013-05-31 P2x7 receptor antagonists and agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018108470A Division JP6681433B2 (ja) 2012-06-01 2018-06-06 Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト

Publications (3)

Publication Number Publication Date
JP2015525211A JP2015525211A (ja) 2015-09-03
JP2015525211A5 JP2015525211A5 (enExample) 2016-07-21
JP6608698B2 true JP6608698B2 (ja) 2019-11-27

Family

ID=48579032

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015514525A Active JP6608698B2 (ja) 2012-06-01 2013-05-31 Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト
JP2018108470A Active JP6681433B2 (ja) 2012-06-01 2018-06-06 Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018108470A Active JP6681433B2 (ja) 2012-06-01 2018-06-06 Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト

Country Status (6)

Country Link
US (2) US9908935B2 (enExample)
EP (1) EP2855518A1 (enExample)
JP (2) JP6608698B2 (enExample)
CN (1) CN104507964B (enExample)
AU (2) AU2013269606B2 (enExample)
WO (1) WO2013178783A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102257003B (zh) 2008-12-19 2017-04-05 埃博灵克斯股份有限公司 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
WO2013178783A1 (en) 2012-06-01 2013-12-05 Ablynx N.V. P2x7 receptor antagonists and agonists
US10071167B2 (en) 2013-05-08 2018-09-11 Children's Medical Center Corporation Method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the ATP/P2X7R axis)
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
SG10201810124PA (en) 2014-05-16 2018-12-28 Ablynx Nv Improved immunoglobulin variable domains
AU2016240410B2 (en) * 2015-04-02 2021-09-16 Biosceptre (Aust) Pty Ltd Pain treatment
WO2017081265A1 (en) * 2015-11-12 2017-05-18 Ablynx Nv Improved p2x7 receptor binders and polypeptides comprising the same
PL233352B1 (pl) * 2016-09-15 2019-10-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe białko fuzyjne
CN109321589A (zh) * 2018-10-15 2019-02-12 潍坊医学院 一种制备p2x7r免疫原的方法
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系
CN115244082A (zh) * 2019-08-23 2022-10-25 新墨西哥大学雨林创新 用于疼痛管理的非阿片类组合物和疗法
KR20230096055A (ko) 2020-11-30 2023-06-29 아사히 가세이 파마 가부시키가이샤 신경병증성 통증 완화용 약물
TW202440614A (zh) 2022-12-23 2024-10-16 比利時商艾伯霖克斯公司 基於蛋白質的接合載體
CN120712282A (zh) 2023-02-17 2025-09-26 阿布林克斯有限公司 结合新生儿fc受体的多肽

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344860B2 (en) 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
CN102257003B (zh) * 2008-12-19 2017-04-05 埃博灵克斯股份有限公司 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
WO2013178783A1 (en) 2012-06-01 2013-12-05 Ablynx N.V. P2x7 receptor antagonists and agonists

Also Published As

Publication number Publication date
US9908935B2 (en) 2018-03-06
AU2013269606A1 (en) 2014-12-18
CA2875234A1 (en) 2013-12-05
JP2015525211A (ja) 2015-09-03
JP6681433B2 (ja) 2020-04-15
AU2018217239A1 (en) 2018-08-30
AU2018217239B2 (en) 2020-07-30
AU2013269606B2 (en) 2018-05-17
CN104507964B (zh) 2020-05-15
US10544216B2 (en) 2020-01-28
CN104507964A (zh) 2015-04-08
US20150133637A1 (en) 2015-05-14
WO2013178783A1 (en) 2013-12-05
JP2018162269A (ja) 2018-10-18
US20180244769A1 (en) 2018-08-30
EP2855518A1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
JP6681433B2 (ja) Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト
JP7708741B2 (ja) Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防
JP7084870B2 (ja) Ｇｉｔｒアゴニスト
JP2022118731A (ja) Ｈｅｒ３抗原結合性分子
JP6181040B2 (ja) 二特異性抗ｃｘｃｒ７免疫グロブリン単一可変ドメイン
JP2013519364A (ja) アゴニストｄｒ５結合ポリペプチド
JP7572147B2 (ja) 抗ｇｉｔｒ抗原結合タンパク質およびその使用方法
AU2016352695B2 (en) Improved P2X7 receptor binders and polypeptides comprising the same
CA3042727A1 (en) Anti-gitr antigen-binding proteins and methods of use thereof
JP2024513644A (ja) Ｖｅｇｆａ結合分子
WO2023186113A1 (zh) 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用
WO2022002006A1 (zh) Fab-HCAb结构的结合蛋白
CA2875234C (en) P2x7 receptor antagonists and agonists
RU2795625C2 (ru) Антигенсвязывающие белки против gitr и способы их применения

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150313

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20151111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170921

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180606

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180614

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190904

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191024

R150 Certificate of patent or registration of utility model

Ref document number: 6608698

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250